豆类丝核菌次级代谢产物的急性毒性与致突变性试验

The acute toxicity and mutagenicity effect of the secondary metabolites of Rhizoctonia leguminicola

通过经口急性毒性试验、小鼠骨髓微核试验和精子畸形试验对豆类丝核菌次级代谢产物的急性毒性和致突变性进行了研究.结果表明,以该代谢产物中苦马豆素的量计算,小鼠经口急性毒性试验的LD50为226.46mg/kg,LD50的95%可信限为158.49～323.59mg/kg,是治疗肿瘤剂量的14～84倍,属于实际低毒级药物.微核试验和精子畸形试验的各试验组与阴性对照组比较差异均不显著(P＞0.05),说明豆类丝核菌次级代谢产物无明显致突变性;各试验组之间比较差异均不显著(P＞0.05),说明微核的形成和精子畸形的形成与受试物无量效关系.结论:豆类丝核菌次级代谢产物是一种较安全的抗肿瘤药物.

The acute toxicity and mutagenicity effect of the secondary metabolites of Rhizoctonia leguminicola containing swainsonine were determined through acute toxicity test,micronucleus test and sperm shape abnormality test.The results showed that LD_50 of the secondary metabolites of Rhizoctonia leguminicola by oral exposure was 226.46 mg/kg.The scope of truth was 158.49-323.59 mg/kg.It was 14-84 times for the cure dosage.So it shuld belong to the actual low poisonous level medicine.The micronucleus rates and sperm shape abnormality rates in all dosage were no significant differences between the exposed groups and the negative group(P>0.05).That is to say the secondary metabolites of Rhizoctonia leguminicola has no mutagenic effect.There are no significant differences among all the exposed group(P>0.05).That is to say there are no quantity-effect relationship among the exposed groups in these two experiments.The results demonstrated the safety for the clinical use of the secondary metabolites of Rhizoctonia leguminicola.